评估 Cordio 可用性和收集患者语音的研发研究
一项观察性、回顾性、单臂、开放式美国和以色列研究,用于可用性评估和算法,Cordio HearO™ 系统的开发
To determine the usability and technical aspects of Cordio HearO™
研究概览
详细说明
The system (including App and server) will be tested under simulated use conditions with representative users to identify potential changes required to the application user interface, to improve user performance and satisfaction, and to inform future design options.
The recordings data will also be used for algorithm improvement
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Ashkelon、以色列
- Barzilai Medical Center- Cardiology
-
Beersheba、以色列
- Heart Failure Clinic - Clallit Be'er Sheva
-
Petah Tikva、以色列、49100
- Rabin Medical Center - Cardiology- CHF
-
-
-
-
Connecticut
-
South Windsor、Connecticut、美国、06074
- Kurker Family Medicine
-
-
Florida
-
Cape Coral、Florida、美国、33904
- C&R Research Services
-
Miami、Florida、美国、33176
- C&R Research Services
-
Miami、Florida、美国、33183
- C&R Research Services
-
-
Georgia
-
Athens、Georgia、美国、31024
- Lake County Med Grp
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult clinical stable patients with NYHA II-IVa (ambulatory)
描述
Major inclusion Criteria:
-
Adults patients
-
Diagnosed with Symptomatic Chronic Heart Failure [NYHA II-IVa (ambulatory)]
-
At least one of the following:
- One ADHF hospitalization in the last 12 months
- One unplanned IV/SC diuretic administration in the last 6 months
- Two unplanned IV/SC diuretic administration in the last 12 months
- NTProBNP >500 pg/ml or BNP*> 150 pg/ml at screening visit
-
Clinically stable HF
-
Willing to participate as evidenced by signing the written informed consent.
-
Male or non-pregnant female patient (pre-menopausal women will confirm verbally).
Major exclusion Criteria:
- Not able to read in Hebrew, Russian, Arabic, English and/or Spanish.
- Unable to comply with daily use of the App
- Major cardiovascular event
- Had a Cardiac Resynchronization Device (CRT) implanted or upgrading ≤ 1 month prior to screening visit.
- Has estimated Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73 meter square (Cockroft-Gault formula).
- Is likely to undergo heart transplantation/ LVAD within 6 months of Screening Visit.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient Usability success defined as: 1.Total and individual usability score of ≥3 in the usability questionnaire in ≥80% of the users.
大体时间:2 years
|
The used scale is: Usability questionnaire for the Cordio HearO™ App. This Usability questionnaire is a subjective evaluation based on Likert score of device user satisfaction. Maximum value for each item: 5 Minimum value for each item: 1 Higher scores means a better outcome |
2 years
|
|
Patient Usability success defined as: 2. Total Compliance
大体时间:2 Years
|
The total compliance will be determined by the total number of recording days. Success will be considered if total average compliance of 70 % of all days. |
2 Years
|
合作者和调查者
调查人员
- 研究主任:Ronit Haviv, PhD、Cordio Medical
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- CLN0016
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.